Samalizumab
| Drug Information | |||
|---|---|---|---|
| Image | |||
| Identifiers
CAS Number ATC Code PubChem DrugBank ChemSpider ID UNII KEGG ChEBI ChEMBL IUPAC Name |
Chemical Data
C H N O Molecular Weight | ||
Samalizumab is an experimental monoclonal antibody designed for the treatment of certain types of cancer and autoimmune diseases. It targets the CD200 receptor, a protein often found on the surface of cancer cells and involved in immune system suppression. By inhibiting this receptor, samalizumab aims to enhance the body's immune response against tumor cells.
Mechanism of Action[edit | edit source]
Samalizumab functions by binding to the CD200 receptor, which is expressed on the surface of certain tumor cells and immune cells. This interaction blocks the immunosuppressive signals sent by tumor cells to the immune system, potentially allowing the immune system to more effectively attack the cancer cells.
Clinical Trials[edit | edit source]
As of the last update, samalizumab has been evaluated in several clinical trials. These studies have primarily focused on assessing its safety, tolerability, and efficacy in patients with various types of cancers, including multiple myeloma, chronic lymphocytic leukemia, and other malignancies that express the CD200 receptor.
Development and Research[edit | edit source]
The development of samalizumab is part of a broader effort to harness the immune system in the fight against cancer. Research into CD200 and its role in cancer and autoimmune disease has suggested that targeting this pathway could be a promising therapeutic strategy.
Potential Side Effects[edit | edit source]
As with any experimental therapy, the use of samalizumab may involve potential side effects. These can vary depending on the individual and the specific nature of the treatment but may include typical immunotherapy side effects such as fatigue, fever, and immune-related adverse events.
Future Prospects[edit | edit source]
The future development of samalizumab will depend on the outcomes of ongoing and future clinical trials. If successful, it could offer a new treatment option for patients with CD200-positive cancers and possibly for certain autoimmune conditions.
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
